ExonateExonate has proprietary mRNA splicing technology and specialises in altering angiogenesis, the formation of new blood vessels. Its first programme, in conjunction with the University of New South Wales in Australia, has a lead candidate for wet age-related macular degeneration. The product is now in pre-clinical trials.